HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.

AbstractBACKGROUND:
This study evaluated the effects of aclidinium bromide, a long-acting muscarinic antagonist indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD), on exercise endurance, dyspnea, lung hyperinflation, and physical activity.
METHODS:
In this randomized, double-blind, crossover study, patients with stable COPD and moderate-to-severe airflow limitation received aclidinium 400 μg twice daily or placebo via Genuair®/Pressair(®a) for 3 weeks (2-week washout between treatment periods). The primary endpoint was change from baseline to Week 3 in endurance time, measured by constant work rate cycle ergometry testing at 75% peak incremental work rate. Changes from baseline in intensity of exertional dyspnea (Borg CR10 Scale®) and trough inspiratory capacity were secondary endpoints. Additional endpoints included changes from baseline in other spirometric, plethysmographic, and physical activity (assessed by objective accelerometer measurement) parameters. Efficacy endpoints were analyzed using an analysis of covariance model.
RESULTS:
In total, 112 patients were randomized and treated (mean age 60.3 years; mean post-bronchodilator forced expiratory volume in 1 s 1.7 L [56.7% predicted]; mean endurance time 485.7 s). After 3 weeks, endurance time was significantly increased with aclidinium versus placebo (treatment difference 58.5 s; p < 0.05). At Week 3, aclidinium significantly reduced dyspnea intensity at isotime during exercise (treatment difference -0.63; p < 0.05) and improved trough inspiratory capacity (treatment difference 78 mL; p < 0.05) versus placebo. Significant improvements in spirometric, plethysmographic, and some physical activity parameters were observed with aclidinium versus placebo.
CONCLUSIONS:
These results suggest that aclidinium significantly improves exercise endurance, exertional dyspnea, hyperinflation, and physical activity in patients with COPD.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier: NCT01471171; URL: http://www.clinicaltrials.gov.
AuthorsKai M Beeh, Henrik Watz, Luis Puente-Maestu, Luis de Teresa, Diana Jarreta, Cynthia Caracta, Esther Garcia Gil, Helgo Magnussen
JournalBMC pulmonary medicine (BMC Pulm Med) Vol. 14 Pg. 209 (Dec 23 2014) ISSN: 1471-2466 [Electronic] England
PMID25539654 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Muscarinic Antagonists
  • Tropanes
  • aclidinium bromide
Topics
  • Accelerometry
  • Aged
  • Cross-Over Studies
  • Double-Blind Method
  • Dyspnea (drug therapy, etiology)
  • Exercise Tolerance
  • Female
  • Forced Expiratory Volume
  • Humans
  • Male
  • Middle Aged
  • Motor Activity
  • Muscarinic Antagonists (therapeutic use)
  • Physical Endurance
  • Pulmonary Disease, Chronic Obstructive (complications, drug therapy)
  • Treatment Outcome
  • Tropanes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: